Viewing Study NCT05512351


Ignite Creation Date: 2025-12-24 @ 11:45 PM
Ignite Modification Date: 2025-12-25 @ 9:38 PM
Study NCT ID: NCT05512351
Status: RECRUITING
Last Update Posted: 2022-09-27
First Post: 2022-08-21
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
Sponsor: Henan Provincial People's Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module